Randomized controlled trial of lymphoblastoid interferon for chronic hepatitis C (Comparison of 9-MU and 6-MU doses)

American Journal of Gastroenterology

Volumn 94, Issue 1, 1999, Pages 164-168

  Yoshioka, Kentaro ^a   Yano, Motoyoshi ^a   Kusakabe, Atsuhiko ^b   Hirofuji, Hideo ^c   Fuji, Akihiko ^d   Kuriki, Junsuke ^e   Arao, Motohiro ^f   Murase, Kenichi ^g   Kidokoro, Ryuichi ^h   Kakumu, Shinichi ⁱ  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c Yokkaichi Municipal Hospital   (Japan)

^d Holy Spirit Hospital   (Japan)

^e Gamagori City Hospital   (Japan)

^f Inazawa Municipal Hospital   (Japan)

^g CHUBU ROSAI HOSPITAL   (Japan)

^h Fukuroi Municipal Hospital   (Japan)

ⁱ AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RNA, VIRAL; VIRAL LOAD;

EID: 0032943949     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00670-4     Document Type: Article

References (26)

1. Choo Q.-L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science. 244:1989;359-362.
2. Kuo G., Choo Q.-L., Alter H.J., et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 244:1989;362-364.
3. Kiyosawa K., Sodeyama T., Tanaka E., et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma Analysis by detection of antibody to hepatitis C virus . Hepatology. 12:1990;671-675.
4. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. N Engl J Med. 321:1989;1501-1506.
5. Di Bisceglie A.M., Martin P., Kassianides C., et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
6. Marcellin P., Boyer N., Giostra E., et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis A multicenter randomized controlled trial from France . Hepatology. 13:1991;393-397.
7. Pagliaro L., Craxi A., Cammaa C., et al. Interferon-alpha for chronic hepatitis C An analysis of pretreatment clinical predictors of response . Hepatology. 19:1994;820-828.
8. Chemello L., Bonetti P., Cavalletto L., et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology. 22:1995;700-706.
9. Shiratori Y., Kato N., Yokosuka O., et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology. 113:1997;558-566.
10. Jacyna M.R., Brooks M.G., Loke R.H.T., et al. Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis. Br Med J. 298:1989;80-82.
11. Castilla A., Camps-Bansell J., Civeira M.-P., et al. Lymphoblastoid α-interferon for chronic hepatitis C A randomized controlled study . Am J Gastroenterol. 88:1993;233-239.
12. Bianchi L., De Groote J., Desmet V.J., et al. Acute and chronic hepatitis revisited Review by an international group . Lancet. 2:1977;914-919.
13. Desmet V.J., Gerber M., Hoofnagle J.H., et al. Classification of chronic hepatitis Diagnosis, grading and staging . Hepatology. 19:1994;1513-1520.
14. Tanaka T., Tsukiyama-Kohara K., Yamaguchi K., et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology. 19:1994;1347-1353.
15. Simmonds P., McOmish F., Yap P.L., et al. Sequence variability in the 5′ non-coding region of hepatitis C virus Identification of a new virus type and restrictions on sequence diversity . J Gen Virol. 74:1993;661-668.
16. Urdea M.S., Horn T., Fultz T.J., et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucl Acids Symp Ser. 24:1991;197-200.
17. Lau J.Y.N., Davis G.L., Kniffen J., et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
18. Yoshioka K., Higashi Y., Yamada M., et al. Predictive factors in the response to interferon therapy in chronic hepatitis C. Liver. 15:1995;57-62.
19. Yoshioka K., Kakumu S., Wakita T., et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy Relationship to genotypes of hepatitis C virus . Hepatology. 16:1992;293-299.
20. Hino K., Okuda M., Konishi T., et al. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapy. Dig Dis Sci. 40:1995;14-20.
21. Orito E., Mizokami M., Suzuki K., et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol. 46:1995;109-115.
22. Kakumu S., Aiyama T., Okumura A., et al. Earlier loss of hepatitis C virus RNA in interferon therapy can predict a long-term response in chronic hepatitis C. J Gastroenterol Hepatol. 12:1997;468-472.
23. Sharara A.I., Hunt C.M., Hamilton J.D. Hepatitis C. Ann Intern Med. 125:1996;658-668.
24. Kasahara A., Hayashi N., Mochizuki K., et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 27:1998;1394-1402.
25. Kakumu S., Yoshioka K., Tanaka K., et al. Long-term carrier state of hepatitis C virus with normal aminotransferase after interferon treatment in patients with chronic hepatitis C. J Med Virol. 41:1993;65-70.
26. Lau J.Y., Mizokami M., Ohno T., et al. Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C. Lancet. 342:1993;1208-1209.